RESUMO
Herein we present highly stable ferromagnetic nickel nanowires modified with streptavidin (NiNW-STR). This versatile functionalized nanomaterial works as an excellent biosensing platform for the immobilization of a wide range of biotinylated molecules. Moreover, these NWs can be employed in magnetic-based assays. Different proofs-of-concept such as streptavidin-biotin assays and capture of single and double stranded DNA were successfully carried out, corroborating NiNW-STR usefulness. Moreover, repeatability and stability studies were also effectively performed.
Assuntos
Nanofios/química , Níquel/química , Estreptavidina/química , Técnicas Biossensoriais , Biotina/química , Biotinilação , Ácidos Nucleicos Imobilizados/química , Fenômenos Magnéticos , ImãsRESUMO
BACKGROUND: The best treatment (steroids, irradiation, or both) for moderately severe Graves' orbitopathy, a self-limiting disease is not known. We tested the efficacy of external beam irradiation compared with sham-irradiation. METHODS: In a double-blind randomised clinical trial, 30 patients with moderately severe Graves' orbitopathy had radiotherapy (20 Gy in ten fractions), and 30 were assigned sham-irradiation (ten fractions of 0 Gy). Treatment outcome was measured qualitatively by changes in major and minor criteria and quantitatively in several ophthalmic and other variables, such as eyelid aperture, proptosis, eye movements, subjective eye score, and clinical-activity score at 24 weeks. FINDINGS: The qualitative treatment outcome was successful in 18 of 30 (60%) irradiated patients versus nine of 29 (31%) sham-irradiated patients at week 24 (relative risk [RR]=1.9 [95% CI 1.0-3.6], p=0.04). This difference was caused by improvements in diplopia grade, but not by reduction of proptosis, nor of eyelid swelling. Quantitatively, elevation improved significantly in the radiotherapy group, whereas all other variables remained unchanged. The field of binocular single vision was enlarged in 11 of 17 patients after irradiation compared with two of 15 after sham-irradiation. Nevertheless, only 25% of the irradiated patients were spared from additional strabismus surgery. INTERPRETATION: In these patients with moderately severe Graves' orbitopathy, radiotherapy should be used only to treat motility impairment.
Assuntos
Doença de Graves/radioterapia , Doenças Orbitárias/radioterapia , Adulto , Relação Dose-Resposta à Radiação , Método Duplo-Cego , Feminino , Doença de Graves/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Orbitárias/diagnóstico , Resultado do TratamentoRESUMO
Acromegaly and hyperprolactinemia have been described in association with polyostotic fibrous dysplasia; the pathogenetic mechanisms involved in the development of the endocrinopathies is unknown. We report a 26-year-old man with polyostotic fibrous dysplasia and hypersecretion of GH and PRL. Plasma GH, PRL, and insulin-like growth factor-I (IGF-I) were elevated. Glucose-non-suppressible plasma GH concentrations, GH responsiveness to TRH and GHRH, and GH suppression after a test-dose of somatostatin, octreotide, and bromocriptine were found. Plasma GHRH levels were within the normal range (< 25 ng/l). Computed tomography of the sella turcica and visual fields were normal. [111In-DTPA-D-Phe1]-octreotide scintigraphy were used to localize a possible tumor; no radioactivity was visualized at the site of the hypothalamus, the pituitary or elsewhere in the body but a considerable accumulation of radioactivity was found in the os frontalis. Therapy with octreotide by continuous sc infusion partially suppressed GH and IGF-I (and normalized PRL). The results suggest that hypersecretion of GH in our patient is not due to a GH-secreting pituitary tumor, eutopic or ectopic hypersecretion of GHRH or autonomous somatotroph function. The origin of the disease in this patient might be an abnormal hypothalamic regulation of somatotrophs and/or an alteration in the transmembrane signalling systems.
Assuntos
Acromegalia/complicações , Acromegalia/tratamento farmacológico , Displasia Fibrosa Monostótica/complicações , Displasia Fibrosa Monostótica/tratamento farmacológico , Hiperprolactinemia/complicações , Hiperprolactinemia/tratamento farmacológico , Octreotida/uso terapêutico , Acromegalia/sangue , Adulto , Bromocriptina/uso terapêutico , Displasia Fibrosa Monostótica/sangue , Hormônio do Crescimento/sangue , Hormônio Liberador de Hormônio do Crescimento/sangue , Humanos , Hiperprolactinemia/sangue , Injeções Subcutâneas , Fator de Crescimento Insulin-Like I/análise , Radioisótopos do Iodo , Masculino , Octreotida/administração & dosagem , Prolactina/sangue , Somatostatina/uso terapêutico , Fatores de TempoRESUMO
The Breast Cancer Mucin (BCM) enzyme immunoassay utilizes two monoclonal antibodies (Mab), M85/34 and F36/22, for the identification of a mucin-like glycoprotein in serum of breast cancer patients. We have compared BCM with CA 15-3, another member of the human mammary epithelial antigen family. Serum BCM was evaluated in 151 and CA 15-3 in 134 patients with breast cancer, in 30 normal controls, in 9 pregnant women, and in 13 cancer patients (non-breast). Neither the normal controls nor the pregnant women had BCM levels greater than 25 U/ml. In contrast, 87 of 115 patients (75%) with metastatic breast cancer had BCM levels greater than 25 U/ml. All control persons had CA 15-3 levels less than 25 U/ml, but 2 out of 9 pregnant women (22%) had levels greater than 25 U/ml. Seventy-four out of 97 patients (76%) with metastatic breast cancer had CA 15-3 levels greater than 25 U/ml. A statistically significant correlation was found between BCM and CA 15-3 in the breast cancer patient group (r = 0.883, p less than 0.001, n = 134) and in the normal control group (r = 0.743, p less than 0.001, n = 30). BCM and CA 15.3 both showed no correlation with CEA in breast cancer patients (r = 0.060, n = 81; and r = 0.146, n = 78, respectively). BCM had a range of sensitivity similar to that of the CA 15-3 RIA. Our results suggest that BCM may be a useful new marker for monitoring the clinical course of patients with breast cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antígenos de Neoplasias/sangue , Antígenos Glicosídicos Associados a Tumores/sangue , Biomarcadores Tumorais/sangue , Neoplasias da Mama/sangue , Neoplasias da Mama/patologia , Antígeno Carcinoembrionário/metabolismo , Feminino , Humanos , Estadiamento de Neoplasias , Gravidez/sangueRESUMO
A case of basal cell adenoma originating in the prostate is presented. This lesion might develop from proliferation of basal epithelial cells of the prostate gland under unknown mechanism.